Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-…
USD105.35+0.34%vs prev. close
Performance
1W
+9.34%
1M
+34.28%
3M
-2.89%
1Y
+270.99%
YTD
+246.39%
Valuation
P/E
—
EPS TTM
-2.13
Dividend yield
—
Size and risk
Market cap
$7.1B
Beta
-0.17
Price history
ORKA price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Oruka Therapeutics
ORKA
Biotechnology
Mkt cap (USD bn)
7.1
P/E
—
Div yld
—
1W
+9.3%
1M
+34.3%
3M
-2.9%
6M
+64.3%
1Y
+271.0%
YTD
+246.4%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Oruka Therapeutics
ORKA
Biotechnology
7.1
—
—
+9.3%
+34.3%
-2.9%
+64.3%
+271.0%
+246.4%
Subscribe to Equity Analytics to compare ORKA with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.